{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:03:08Z","timestamp":1791601388742,"version":"4.3.4"},"reference-count":22,"publisher":"Society of Nuclear Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2024,4,25]]},"published-print":{"date-parts":[[2024,7]]},"DOI":"10.2967\/jnumed.124.267416","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T14:50:23Z","timestamp":1716475823000},"page":"1051-1056","source":"Crossref","is-referenced-by-count":12,"title":["A Phase 0 Study to Assess the Biodistribution and Pharmacokinetics of a Radiolabeled Antibody Targeting Human Kallikrein 2 in Participants with Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.2967","volume":"65","author":[{"given":"Neeta","family":"Pandit-Taskar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"O\u2019Donoghue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dushen","family":"Chetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Max","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Wanik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ohad","family":"Ilovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tenzin","family":"Nyima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaitanya R.","family":"Divgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2024,5,23]]},"reference":[{"key":"2024070106251405000_65.7.1051.1","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. National Comprehensive Cancer Network website. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Updated March 2024. Accessed May 2, 2024."},{"key":"2024070106251405000_65.7.1051.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2021.11.033"},{"key":"2024070106251405000_65.7.1051.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2024070106251405000_65.7.1051.4","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3390\/biomedicines10030537","article-title":"Immunotherapy in advanced prostate cancer: current knowledge and future directions","volume":"10","author":"L\u00f3pez-Campos","year":"2022","journal-title":"Biomedicines."},{"key":"2024070106251405000_65.7.1051.5","doi-asserted-by":"crossref","first-page":"S974","DOI":"10.1016\/j.annonc.2023.09.2752","article-title":"1804P APEX-01: first-in-human phase I\/II study of ARX517 an anti-prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"34","author":"Shen","year":"2023","journal-title":"Ann Oncol."},{"key":"2024070106251405000_65.7.1051.6","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S"},{"key":"2024070106251405000_65.7.1051.7","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.1501"},{"key":"2024070106251405000_65.7.1051.8","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1038\/s41467-018-04107-w","article-title":"Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer","volume":"9","author":"McDevitt","year":"2018","journal-title":"Nat Commun."},{"key":"2024070106251405000_65.7.1051.9","doi-asserted-by":"publisher","DOI":"10.1160\/TH13-04-0275"},{"key":"2024070106251405000_65.7.1051.10","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1097\/01.ju.0000086640.19892.0b","article-title":"Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer","volume":"170","author":"Becker","year":"2003","journal-title":"J Urol."},{"key":"2024070106251405000_65.7.1051.11","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/clinchem\/42.7.1034","article-title":"Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum","volume":"42","author":"Piironen","year":"1996","journal-title":"Clin Chem."},{"key":"2024070106251405000_65.7.1051.12","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s13277-013-1253-6","article-title":"Human kallikrein 2 (KLK2) promotes prostate cancer cell growth via function as a modulator to promote the ARA70-enhanced androgen receptor transactivation","volume":"35","author":"Shang","year":"2014","journal-title":"Tumour Biol."},{"key":"2024070106251405000_65.7.1051.13","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.eururo.2016.07.033","article-title":"Subgroups of castration-resistant prostate cancer bone metastases defined through an inverse relationship between androgen receptor activity and immune response","volume":"71","author":"Ylitalo","year":"2017","journal-title":"Eur Urol."},{"key":"2024070106251405000_65.7.1051.14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1106383108"},{"key":"2024070106251405000_65.7.1051.15","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-0892"},{"key":"2024070106251405000_65.7.1051.16","unstructured":"Gene page. GTExPortal website. http:\/\/gtexportal.org\/home\/gene\/KLK2. Updated April 11, 2024. Accessed May 2, 2024."},{"key":"2024070106251405000_65.7.1051.17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13550-014-0051-5","article-title":"Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a 111In-radiolabelled monoclonal antibody, 11B6","volume":"4","author":"Timmermand","year":"2014","journal-title":"EJNMMI Res."},{"key":"2024070106251405000_65.7.1051.18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0552"},{"key":"2024070106251405000_65.7.1051.19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13550-015-0104-4","article-title":"Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors","volume":"5","author":"Pandit-Taskar","year":"2015","journal-title":"EJNMMI Res."},{"key":"2024070106251405000_65.7.1051.20","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-05057-6"},{"key":"2024070106251405000_65.7.1051.21","doi-asserted-by":"crossref","first-page":"TPS206","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS206","article-title":"A study of JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2 (hK2) for advanced prostate cancer [abstract]","volume":"40","author":"Morris","year":"2022","journal-title":"J Clin Oncol."},{"key":"2024070106251405000_65.7.1051.22","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf2335"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.124.267416","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T13:28:46Z","timestamp":1719840526000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.124.267416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,23]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,1]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.2967\/jnumed.124.267416"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.124.267416","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,23]]}}}